Literature DB >> 30817990

Isolated glucocorticoid deficiency: Genetic causes and animal models.

Avinaash Maharaj1, Ashwini Maudhoo1, Li F Chan1, Tatiana Novoselova1, Rathi Prasad1, Louise A Metherell1, Leonardo Guasti2.   

Abstract

Hereditary adrenocorticotropin (ACTH) resistance syndromes encompass the genetically heterogeneous isolated or Familial Glucocorticoid Deficiency (FGD) and the distinct clinical entity known as Triple A syndrome. The molecular basis of adrenal resistance to ACTH includes defects in ligand binding, MC2R/MRAP receptor trafficking, cellular redox balance, cholesterol synthesis and sphingolipid metabolism. Biochemically, this manifests as ACTH excess in the setting of hypocortisolaemia. Triple A syndrome is an inherited condition involving a tetrad of adrenal insufficiency, achalasia, alacrima and neuropathy. FGD is an autosomal recessive condition characterized by the presence of isolated glucocorticoid deficiency, classically in the setting of preserved mineralocorticoid secretion. Primarily there are three established subtypes of the disease: FGD 1, FGD2 and FGD3 corresponding to mutations in the Melanocortin 2 receptor MC2R (25%), Melanocortin 2 receptor accessory protein MRAP (20%), and Steroidogenic acute regulatory protein STAR (5-10%) respectively. Together, mutations in these 3 genes account for approximately half of cases. Whole exome sequencing in patients negative for MC2R, MRAP and STAR mutations, identified mutations in minichromosome maintenance 4 MCM4, nicotinamide nucleotide transhydrogenase NNT, thioredoxin reductase 2 TXNRD2, cytochrome p450scc CYP11A1, and sphingosine 1-phosphate lyase SGPL1 accounting for a further 10% of FGD. These novel genes have linked replicative and oxidative stress and altered redox potential as a mechanism of adrenocortical damage. However, a genetic diagnosis is still unclear in about 40% of cases. We describe here an updated list of FGD genes and provide a description of relevant mouse models that, despite some being flawed, have been precious allies in the understanding of FGD pathobiology.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ACTH resistance; Familial glucocorticoid deficiency; Isolated glucocorticoid deficiency

Mesh:

Substances:

Year:  2019        PMID: 30817990     DOI: 10.1016/j.jsbmb.2019.02.012

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  3 in total

Review 1.  ACTH signalling and adrenal development: lessons from mouse models.

Authors:  Tatiana V Novoselova; Peter J King; Leonardo Guasti; Louise A Metherell; Adrian J L Clark; Li F Chan
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

Review 2.  Pediatric Adrenal Insufficiency: Challenges and Solutions.

Authors:  Daniela Nisticò; Benedetta Bossini; Simone Benvenuto; Maria Chiara Pellegrin; Gianluca Tornese
Journal:  Ther Clin Risk Manag       Date:  2022-01-11       Impact factor: 2.423

3.  Genetic Analysis of Pediatric Primary Adrenal Insufficiency of Unknown Etiology: 25 Years' Experience in the UK.

Authors:  Federica Buonocore; Avinaash Maharaj; Younus Qamar; Katrin Koehler; Jenifer P Suntharalingham; Li F Chan; Bruno Ferraz-de-Souza; Claire R Hughes; Lin Lin; Rathi Prasad; Jeremy Allgrove; Edward T Andrews; Charles R Buchanan; Tim D Cheetham; Elizabeth C Crowne; Justin H Davies; John W Gregory; Peter C Hindmarsh; Tony Hulse; Nils P Krone; Pratik Shah; M Guftar Shaikh; Catherine Roberts; Peter E Clayton; Mehul T Dattani; N Simon Thomas; Angela Huebner; Adrian J Clark; Louise A Metherell; John C Achermann
Journal:  J Endocr Soc       Date:  2021-05-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.